Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.

Satoh T, Barthélémy P, Nogova L, Honda K, Hirano H, Lee KW, Rha SY, Ryu MH, Park JO, Doi T, Ajani J, Hangai N, Kremer J, Mina M, Liu M, Shitara K.

Open source

DOI: 10.1016/j.ejca.2025.115262
Published: 2025-01-27
Container: Eur J Cancer
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.115262,
  title = {Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.},
  author = {Satoh T and  Barthélémy P and  Nogova L and  Honda K and  Hirano H and  Lee KW and  Rha SY and  Ryu MH and  Park JO and  Doi T and  Ajani J and  Hangai N and  Kremer J and  Mina M and  Liu M and  Shitara K.},
  year = {2025},
  journal = {Eur J Cancer},
  doi = {10.1016/j.ejca.2025.115262},
  url = {https://doi.org/10.1016/j.ejca.2025.115262}
}

RIS

TY  - JOUR
TI  - Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.
AU  - Satoh T
AU  -  Barthélémy P
AU  -  Nogova L
AU  -  Honda K
AU  -  Hirano H
AU  -  Lee KW
AU  -  Rha SY
AU  -  Ryu MH
AU  -  Park JO
AU  -  Doi T
AU  -  Ajani J
AU  -  Hangai N
AU  -  Kremer J
AU  -  Mina M
AU  -  Liu M
AU  -  Shitara K.
PY  - 2025
JO  - Eur J Cancer
DO  - 10.1016/j.ejca.2025.115262
UR  - https://doi.org/10.1016/j.ejca.2025.115262
ER  -

APA

T, S., P, B., L, N., K, H., H, H., KW, L., SY, R., MH, R., JO, P., T, D., J, A., N, H., J, K., M, M., M, L., & K., S. (2025). Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.. Eur J Cancer. https://doi.org/10.1016/j.ejca.2025.115262

Source records

europe-pmc · retrieved 2026-09-25T23:35:44.342Z